Published in N Engl J Med on March 30, 2008
The metabolic syndrome. Endocr Rev (2008) 5.33
Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med (2014) 4.94
Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab (2009) 3.98
Does ENHANCE diminish confidence in lowering LDL or in ezetimibe? N Engl J Med (2008) 3.59
Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation (2008) 3.48
Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48
Conflicts of interest, authorship, and disclosures in industry-related scientific publications: the tort bar and editorial oversight of medical journals. Mayo Clin Proc (2009) 3.48
Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers. Nat Rev Drug Discov (2010) 2.63
Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ (2008) 2.62
Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J (2008) 2.50
Reporting bias in medical research - a narrative review. Trials (2010) 2.44
Traditional risk factors are not major contributors to the variance in carotid intima-media thickness. Stroke (2013) 2.34
Demystifying the management of hypertriglyceridaemia. Nat Rev Cardiol (2013) 2.17
The importance of clinical trial data sharing: toward more open science. Circ Cardiovasc Qual Outcomes (2012) 2.16
Pleiotropic effects of statins. - Basic research and clinical perspectives -. Circ J (2010) 2.13
Familial hypercholesterolemia: developments in diagnosis and treatment. Dtsch Arztebl Int (2014) 2.12
The impact of clinical trials legislation on clinical pharmacology: problems and solutions. Br J Clin Pharmacol (2009) 1.96
Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol (2008) 1.91
Dyslipidemia in youth with diabetes: to treat or not to treat? J Pediatr (2008) 1.72
The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis (2011) 1.70
Statin Use and Adrenal Aldosterone Production in Hypertensive and Diabetic Subjects. Circulation (2015) 1.67
Molecular processes that handle -- and mishandle -- dietary lipids. J Clin Invest (2008) 1.60
Risk factors for venous and arterial thrombosis. Blood Transfus (2010) 1.58
Low-density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease. J Am Coll Cardiol (2011) 1.58
Consensus statement on management of dyslipidemia in Indian subjects. Indian Heart J (2014) 1.57
Relation of different measures of low-density lipoprotein cholesterol to risk of coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapy. Am J Cardiol (2010) 1.53
Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat Rev Drug Discov (2011) 1.48
Promoting transparency in pharmaceutical industry-sponsored research. Am J Public Health (2011) 1.46
MR imaging of carotid plaque composition during lipid-lowering therapy a prospective assessment of effect and time course. JACC Cardiovasc Imaging (2011) 1.29
Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport. Annu Rev Physiol (2011) 1.28
Dyslipidemia and its Treatment in HIV Infection. Top HIV Med (2010) 1.24
Comparison of the effects of maximal dose atorvastatin and rosuvastatin therapy on cholesterol synthesis and absorption markers. J Lipid Res (2008) 1.21
Identification of novel inhibitors of dietary lipid absorption using zebrafish. PLoS One (2010) 1.20
Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol (2014) 1.20
NPC1L1 and cholesterol transport. FEBS Lett (2010) 1.19
Optimal management of familial hypercholesterolemia: treatment and management strategies. Vasc Health Risk Manag (2010) 1.16
Cardiovascular magnetic resonance parameters of atherosclerotic plaque burden improve discrimination of prior major adverse cardiovascular events. J Cardiovasc Magn Reson (2009) 1.14
Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal. PLoS One (2010) 1.14
End points for clinical trials in acute heart failure syndromes. J Am Coll Cardiol (2009) 1.13
Exercise training in aging and diseases. Transl Med UniSa (2012) 1.11
Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr Pharm Des (2009) 1.09
Reconsidering the placebo response from a broad anthropological perspective. Cult Med Psychiatry (2009) 1.05
Ezetimibe reduces plaque inflammation in a rabbit model of atherosclerosis and inhibits monocyte migration in addition to its lipid-lowering effect. Br J Pharmacol (2009) 1.04
Management of cardiovascular disease in patients with diabetes: the 2008 Canadian Diabetes Association guidelines. CMAJ (2008) 1.04
Novel genetic variants linked to coronary artery disease by genome-wide association are not associated with carotid artery intima-media thickness or intermediate risk phenotypes. Atherosclerosis (2008) 1.04
Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9. J Lipid Res (2011) 1.01
Baseline cholesterol absorption and the response to ezetimibe/simvastatin therapy: a post-hoc analysis of the ENHANCE trial. J Lipid Res (2009) 1.00
Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag (2012) 0.99
Effects of ezetimibe add-on therapy for high-risk patients with dyslipidemia. Lipids Health Dis (2009) 0.97
Thyroid hormones and thyroid hormone receptors: effects of thyromimetics on reverse cholesterol transport. World J Gastroenterol (2010) 0.96
Cholesterol lowering and ezetimibe. N Engl J Med (2008) 0.96
Diminishing efficacy of combination therapy, response-heterogeneity, and treatment intolerance limit the attainability of tight risk factor control in patients with diabetes. Health Serv Res (2010) 0.95
Clinical and research applications of carotid intima-media thickness. Am J Cardiol (2009) 0.94
Reference intervals for serum total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, Lp (a), apolipoprotein A-I, A-II, B, C-II, C-III, and E in healthy South Indians from Andhra Pradesh. Indian J Clin Biochem (2009) 0.93
Abolished synthesis of cholic acid reduces atherosclerotic development in apolipoprotein E knockout mice. J Lipid Res (2010) 0.92
Risk factor management to prevent first stroke. Neurol Clin (2008) 0.92
American Diabetes Association indications for statins in diabetes: is there evidence? Diabetes Care (2009) 0.92
Familial hypercholesterolemia: A review. Ann Pediatr Cardiol (2014) 0.91
MR plaque imaging of the carotid artery. Neuroradiology (2010) 0.91
The search beyond statins. Nat Med (2010) 0.90
State variation in AIDS drug assistance program prescription drug coverage for modifiable cardiovascular risk factors. J Gen Intern Med (2011) 0.90
CKD, plasma lipids, and common carotid intima-media thickness: results from the multi-ethnic study of atherosclerosis. Clin J Am Soc Nephrol (2012) 0.90
A cross-sectional study of intima-media thickness, ethnicity, metabolic syndrome, and cardiovascular risk in 2268 study participants. Mayo Clin Proc (2009) 0.89
Are the new guidelines for the use of lipid-lowering agents sound, and should their adoption be encouraged? Can J Hosp Pharm (2014) 0.89
Increasing spatial resolution of 3T MRI scanning improves reproducibility of carotid arterial wall dimension measurements. MAGMA (2013) 0.89
Measuring hsCRP--an important part of a comprehensive risk profile or a clinically redundant practice? PLoS Med (2010) 0.89
The relationships of markers of cholesterol homeostasis with carotid intima-media thickness. PLoS One (2010) 0.88
Therapeutic strategies to deplete macrophages in atherosclerotic plaques. Br J Clin Pharmacol (2012) 0.88
Effects of statins on the epicardial fat thickness in patients with coronary artery stenosis underwent percutaneous coronary intervention: comparison of atorvastatin with simvastatin/ezetimibe. J Cardiovasc Ultrasound (2010) 0.87
Proof of concept in cardiovascular risk: the paradoxical findings in blood pressure and lipid abnormalities. Vasc Health Risk Manag (2012) 0.87
Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia. Arch Med Sci (2011) 0.87
Reduced LDL-cholesterol levels in patients with coronary artery disease are paralleled by improved endothelial function: An observational study in patients from 2003 and 2007. Atherosclerosis (2010) 0.86
Treatment of risk factors to prevent stroke. Neurotherapeutics (2011) 0.86
Lipid management in patients who have HIV and are receiving HIV therapy. Endocrinol Metab Clin North Am (2009) 0.86
Familial hypercholesterolemia: present and future management. Curr Cardiol Rep (2011) 0.86
Carotid plaque regression following 6-month statin therapy assessed by 3T cardiovascular magnetic resonance: comparison with ultrasound intima media thickness. J Cardiovasc Magn Reson (2011) 0.86
Translational biomarkers: from preclinical to clinical a report of 2009 AAPS/ACCP Biomarker Workshop. AAPS J (2011) 0.85
End points for comparative effectiveness research in heart failure. Heart Fail Clin (2012) 0.85
Intestinal and hepatic niemann-pick c1-like 1. Diabetes Metab J (2013) 0.85
Carotid intima-media thickness studies: study design and data analysis. J Stroke (2013) 0.84
The "Mevalonate hypothesis": a cholesterol-independent alternative for the etiology of atherosclerosis. Lipids Health Dis (2012) 0.84
Impact of the ENHANCE trial on the use of ezetimibe in the United States and Canada. Am Heart J (2014) 0.84
Discovery and validation of new molecular targets in treating dyslipidemia: the role of human genetics. Trends Cardiovasc Med (2009) 0.84
Association between triglycerides and cardiovascular events in primary populations: a meta-regression analysis and synthesis of evidence. Vasc Health Risk Manag (2013) 0.84
Moderately decreased cholesterol absorption rates are associated with a large atheroprotective effect. Arterioscler Thromb Vasc Biol (2009) 0.84
Association between cholesterol synthesis/absorption markers and effects of cholesterol lowering by atorvastatin among patients with high risk of coronary heart disease. J Lipid Res (2013) 0.84
Management of patients with familial hypercholesterolaemia. Nat Rev Cardiol (2015) 0.83
Management of dyslipidemia in HIV-infected patients. Clin Lipidol (2011) 0.83
Impact of ezetimibe on atherosclerosis: is the jury still out? Mayo Clin Proc (2009) 0.83
Effect of ezetimibe on major atherosclerotic disease events and all-cause mortality. Am J Cardiol (2012) 0.83
Safety of simvastatin and goal attainment for low-density lipoprotein cholesterol in sultan qaboos university hospital. Oman Med J (2010) 0.83
Clinical efficacy and safety of Ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trials. PLoS One (2015) 0.82
Mipomersen and other therapies for the treatment of severe familial hypercholesterolemia. Vasc Health Risk Manag (2012) 0.82
Role of lipotoxicity in endothelial dysfunction. Heart Fail Clin (2012) 0.82
Impact of efavirenz on intestinal metabolism and transport: insights from an interaction study with ezetimibe in healthy volunteers. Clin Pharmacol Ther (2012) 0.82
Atherosclerosis: current status of prevention and treatment. Int J Angiol (2011) 0.82
The associations of cholesterol metabolism and plasma plant sterols with all-cause and cardiovascular mortality. J Lipid Res (2010) 0.81
Cardiovascular risk assessment and cholesterol management in adolescents: getting to the heart of the matter. Curr Opin Pediatr (2010) 0.81
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet (2010) 17.89
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature (2011) 13.25
Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet (2009) 12.44
Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet (2008) 12.32
Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation (2007) 11.95
Genome-wide association study of blood pressure and hypertension. Nat Genet (2009) 11.54
Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet (2012) 11.09
Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol (2005) 10.56
Pneumatic dilation versus laparoscopic Heller's myotomy for idiopathic achalasia. N Engl J Med (2011) 6.76
Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med (2015) 6.12
Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA (2007) 6.02
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol (2003) 5.77
Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA (2013) 4.82
Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J (2008) 4.74
High serum uric acid as a novel risk factor for type 2 diabetes. Diabetes Care (2007) 4.69
Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet (2011) 4.67
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet (2012) 4.63
A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet (2012) 4.37
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med (2014) 4.14
Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol (2012) 4.13
Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet (2014) 4.13
Evaluation of common variants in the six known maturity-onset diabetes of the young (MODY) genes for association with type 2 diabetes. Diabetes (2007) 3.84
Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation (2003) 3.81
Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. Circulation (2011) 3.68
Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA (2012) 3.67
Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol (2002) 3.64
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J (2013) 3.58
Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA (2004) 3.55
Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging--a meta-analysis. Radiology (2004) 3.55
Predicting type 2 diabetes based on polymorphisms from genome-wide association studies: a population-based study. Diabetes (2008) 3.54
Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet (2011) 3.40
ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. JAMA (2009) 3.33
Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev (2009) 3.25
Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet (2013) 3.25
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med (2012) 3.15
Quantifying the association between gene expressions and DNA-markers by penalized canonical correlation analysis. Stat Appl Genet Mol Biol (2008) 3.13
Relation between blood pressure and vascular events and mortality in patients with manifest vascular disease: J-curve revisited. Hypertension (2011) 3.11
Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam Study. Circulation (2004) 2.90
Carotid intima-media thickness in the Spanish population: reference ranges and association with cardiovascular risk factors. Rev Esp Cardiol (Engl Ed) (2012) 2.78
"Refractory" eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids. Am J Respir Crit Care Med (2004) 2.77
In vivo cell seeding with anti-CD34 antibodies successfully accelerates endothelialization but stimulates intimal hyperplasia in porcine arteriovenous expanded polytetrafluoroethylene grafts. Circulation (2005) 2.69
Arterial stiffness is increased in families with premature coronary artery disease. Heart (2011) 2.68
Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat Genet (2008) 2.67
Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ (2008) 2.62
Comprehensive association testing of common mitochondrial DNA variation in metabolic disease. Am J Hum Genet (2006) 2.60
Peri-coronary epicardial adipose tissue is related to cardiovascular risk factors and coronary artery calcification in post-menopausal women. Eur Heart J (2007) 2.60
Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med (2003) 2.56
Lipoprotein lipase S447X: a naturally occurring gain-of-function mutation. Arterioscler Thromb Vasc Biol (2006) 2.55
Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. J Am Soc Nephrol (2012) 2.55
Haplotype structure and genotype-phenotype correlations of the sulfonylurea receptor and the islet ATP-sensitive potassium channel gene region. Diabetes (2004) 2.52
High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol (2008) 2.51
Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2012) 2.49
High dietary glycemic load and glycemic index increase risk of cardiovascular disease among middle-aged women: a population-based follow-up study. J Am Coll Cardiol (2007) 2.47
Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res (2005) 2.46
A largely random AAV integration profile after LPLD gene therapy. Nat Med (2013) 2.42
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med (2007) 2.41
Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study. Lancet (2002) 2.39
Measuring carotid intima-media thickness: extensive ultrasound protocols have value. J Am Soc Echocardiogr (2012) 2.39
Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur Heart J (2013) 2.37
Asymptomatic carotid artery stenosis and the risk of new vascular events in patients with manifest arterial disease: the SMART study. Stroke (2007) 2.36
Preoperative thresholds for pulmonary valve replacement in patients with corrected tetralogy of Fallot using cardiovascular magnetic resonance. Circulation (2007) 2.31
Evaluation of risk prediction updates from commercial genome-wide scans. Genet Med (2009) 2.30
Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol (2007) 2.29
Risk factors for malignant ventricular arrhythmias in lamin a/c mutation carriers a European cohort study. J Am Coll Cardiol (2012) 2.28
Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia. J Lipid Res (2002) 2.28
TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proc Natl Acad Sci U S A (2007) 2.28
Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Ann Intern Med (2007) 2.26
Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol (2007) 2.22
Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol (2013) 2.18
Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation (2007) 2.15
The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res (2007) 2.15
Magnetic resonance imaging to assess the hemodynamic effects of pulmonary valve replacement in adults late after repair of tetralogy of fallot. Circulation (2002) 2.14
Interactions of dietary whole-grain intake with fasting glucose- and insulin-related genetic loci in individuals of European descent: a meta-analysis of 14 cohort studies. Diabetes Care (2010) 2.14
Exhaled breath profiling enables discrimination of chronic obstructive pulmonary disease and asthma. Am J Respir Crit Care Med (2009) 2.12
Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol (2008) 2.10
Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol (2002) 2.09
Risk of deep vein thrombosis and pulmonary embolism in asthma. Eur Respir J (2012) 2.08
New risk factors for atherosclerosis and patient risk assessment. Circulation (2004) 2.07
Improvement of risk prediction by genomic profiling: reclassification measures versus the area under the receiver operating characteristic curve. Am J Epidemiol (2010) 2.06